SentinelOne Inc. Class A Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? SentinelOne Inc. Class A Common Stock trades at $25.4 (market cap $8.81B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while SentinelOne Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SentinelOne Inc. Class A Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| S | ZBH | |
|---|---|---|
Market Cap | $8.81B | $16.88B |
Volume | 8,035,068 | 1,991,354 |
Sector | Technology | Health |
52-Week High | $25.80 | $103.98 |
52-Week Low | $11.94 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $8.20B | $23.95B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →